The project will help the company keep pace with a growing demand for the development and use of biologics, which currently represents nearly 50% of its overall pipeline.
AstraZeneca regional vice-president of biologics supply Andrew Skibo said: "Biologics are an important part of AstraZeneca’s overall capabilities, in addition to our strengths in small molecules and protein engineering.
"Our global biologics research and development arm, MedImmune, has a robust pipeline of more than 120 biologics, including more than 30 in clinical development.
"The expansion of our Frederick facility will support the progression of drug candidates across our core therapeutic areas, ultimately aiding us in our efforts to make a meaningful difference in the lives of patients through scientific leadership and innovative new treatments."
Scheduled to be initiated in December, expansion at the FDA licensed Frederick biologics manufacturing center is expected to be completed in mid-2017.
The expansion will add 40,000ft² of manufacturing, laboratory and administrative space and bring 300 new jobs to the site.
The Frederick manufacturing center currently produces a pediatric medication, as well as other investigational biologic products.